SGLT2抑制剂与DPP4抑制剂在合并痴呆的老年糖尿病患者中的心血管有效性与安全性
该研究基于加拿大安大略省行政数据,采用目标试验模拟队列设计,纳入2016-2022年≥66岁新启用SGLT2i或DPP4i的糖尿病患者,按痴呆状态分层并1:1倾向评分匹配。结果显示,合并痴呆者使用SGLT2i相比DPP4i的心血管复合终点绝对风险降低更显著(IRD -61.1/1000人年,NNT 20),但酮症酸中毒绝对风险增加也更明显,提示需加强监测。
要点
- 合并痴呆的老年糖尿病患者使用SGLT2i较DPP4i显著降低全因死亡或心血管住院复合终点(NNT 20)。
- 合并痴呆者使用SGLT2i的全因死亡和心衰住院风险降低,急性肾损伤减少,但生殖器感染增加。
- 合并痴呆者使用SGLT2i的酮症酸中毒绝对风险增加更明显(NNH 109),需密切监测。
核心结论
- 在合并痴呆的老年糖尿病患者中,SGLT2i较DPP4i可能提供心肾保护,但酮症酸中毒易感性更高,需更密切监测。
研究设计与样本
- 基于加拿大安大略省行政数据的群体性目标试验模拟队列研究,纳入2016-2022年≥66岁新启用SGLT2i或DPP4i的糖尿病患者,按痴呆状态分层并1:1倾向评分匹配。
- 分析2481对合并痴呆者和52196对无痴呆者。
主要发现
- 合并痴呆者中,SGLT2i vs DPP4i的复合有效性终点绝对降低更显著(IRD -61.1 [-78.2, -43.9]/1000人年;NNT 20),无痴呆者为IRD -21.7 [-23.7, -19.7];NNT 43; homogeneity p<0.001。
- 合并痴呆者中,SGLT2i vs DPP4i与全因死亡降低(IRD -51.2 [-65.7, -36.7];NNT 25)和心衰住院降低(IRD -16.4 [-24.6, -8.2];NNT 99)相关。
- 安全性方面,合并痴呆者中SGLT2i vs DPP4i的急性肾损伤减少(IRD -39.7 [-55.0, -24.4];NNT 76),生殖器感染增加(IRD 9.7 [3.7, 15.6];NNH 64)。
- 合并痴呆者中SGLT2i的酮症酸中毒绝对增加更明显(IRD 1.1 [0.7, 1.6] vs 5.9 [2.1, 9.8];NNH 785 vs 109;homogeneity p=0.015)。
临床怎么用
- 对合并痴呆的老年糖尿病患者,SGLT2i可优先考虑用于心血管和肾脏保护。
- 使用SGLT2i时需警惕酮症酸中毒风险,尤其合并痴呆者应加强监测。
- 关注生殖器感染风险,必要时采取预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: People with dementia are at a higher risk of inappropriate medication use; however, limited data inform clinical outcomes of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in people with diabetes and comorbid dementia. We aim to investigate cardiovascular effectiveness and safety of SGLT2i vs dipeptidyl peptidase-4 inhibitors (DPP4i) in older community-dwelling adults with diabetes by dementia status. METHODS: This population-based, target trial emulation cohort study used linkable administrative datasets of residents of Ontario, Canada. Eligible initiators of SGLT2i or DPP4i with diabetes aged ≥66 years (2016-2022) were stratified by dementia status and matched 1:1 on propensity score. The primary cardiovascular effectiveness outcome was composite of all-cause mortality or hospitalisation for ischaemic stroke, myocardial infarction or heart failure. We also investigated eight safety outcomes potentially related to SGLT2i. Incidence rate differences (IRDs) per 1000 person-years and the 95% CIs were estimated. Homogeneity in IRDs between strata was assessed using the Cochran's Q statistic. One year number needed to treat (NNT) or harm (NNH) was also estimated using the Aalen-Johansen estimator with death as a competing risk. RESULTS: We analysed 2481 pairs with dementia and 52,196 pairs without dementia. The absolute reduction in the composite effectiveness endpoint with SGLT2i vs DPP4i initiation was greater among those with dementia (IRD [95% CI] -61.1 [-78.2, -43.9]; NNT: 20), compared to no dementia (IRD -21.7 [-23.7, -19.7]; NNT: 43; homogeneity: p<0.001). Across the individual effectiveness endpoints, SGLT2i vs DPP4i initiation in people with dementia was associated with reduced all-cause mortality (IRD -51.2 [-65.7, -36.7]; NNT: 25) and hospitalisation for heart failure (IRD -16.4 [-24.6, -8.2]; NNT: 99). For safety outcomes, SGLT2i vs DPP4i initiators with dementia showed less acute kidney injury (IRD -39.7 [-55.0, -24.4]; NNT: 76) and increased genital infection (IRD 9.7 [3.7, 15.6]; NNH: 64). The absolute increase in diabetic ketoacidosis (IRD 1.1 [0.7, 1.6] vs 5.9 [2.1, 9.8]; NNH: 785 vs 109; homogeneity: p=0.015) with SGLT2i was greater among those with dementia vs no dementia. CONCLUSIONS/INTERPRETATION: While SGLT2i might provide cardiorenal protection among those with dementia, closer monitoring may be warranted due to greater susceptibility to diabetic ketoacidosis.
引用
- Wu CY, Sharma A, Edwards JD, et al. Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes. Diabetologia. 2025. PMID: 41204979. doi:10.1007/s00125-025-06595-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。